Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient.

Abstract

During the last decades, the introduction of new cytotoxics and targeted therapies resulted in a prolongation of survival and a minimization of toxicity in the treatment of metastatic breast cancer. However, to date, there was no standard of care following second-line therapy in this setting. In Phase III EMBRACE study, eribulin obtained a statistically significant improvement in the overall survival of pretreated metastatic breast cancer patients. This case report describes a heavily chemo-pretreated woman with important bone, nodal, hepatic and choroidal involvement from breast cancer who had a remarkable, unexpected and lasting disease response after treatment with eribulin. This case underlines how this well-tolerated monochemotherapy may be able to obtain a prolonged disease control and a good clinical outcome.

• Authors: Giuseppina Rosaria Rita Ricciardi, Claudia Proto, Giuseppa Ferraro, Vincenzo Adamo
• Journal: Future oncology (London, England) (Future Oncol) Vol. 10 Issue 15 Pg. 2417-22 (Dec 2014) ISSN: 1744-8301 [Electronic] England
• PMID: 25525850 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antimitotic Agents
• Furans
• Ketones
• eribulin

Topics

• Antimitotic Agents (therapeutic use)
• Breast Neoplasms (diagnosis, drug therapy, pathology)
• Eye Neoplasms (diagnosis, secondary)
• Female
• Furans (therapeutic use)
• Humans
• Ketones (therapeutic use)
• Middle Aged
• Treatment Outcome